Search

Thierry H Bussiere

from Belmont, MA
Age ~56
Get Report
Also known as:
Thierr Bussiere, Thierry Bussier, Bussiere Thierry
Phone and address:
7 Gorham Rd, Belmont, MA 02478
(617) 993-3140
Connected to:
Aaron O Bussiere, 54Alexandra L Bussiere, 33Brandon Bussiere, 37Christian Bussiere, 32Courtney R Bussiere, 29Curt R Bussiere, 52Dennis R Bussiere, 83Jennifer A Bussies, 48Louise Bussiere, 83Tonya L Bussiere, 49

Thierry Bussiere Phones & Addresses

  • 7 Gorham Rd, Belmont, MA 02478 (617) 993-3140
  • 572 Trapelo Rd, Belmont, MA 02478
  • Cambridge, MA
  • Atlanta, GA
  • 1 Bayside Village Pl, San Francisco, CA 94107
  • 333 93Rd St, New York, NY 10128

Work

Company: Biogen idec Feb 2008 Address: Greater Boston Area Position: Senior scientist - neurology research

Education

Degree: PhD School / High School: Université des Sciences et Technologies de Lille (Lille I) 1995 to 1998 Specialities: Sciences de la Vie et de la Sante - Neuroscience

Skills

Neuroscience • Drug Discovery • Immunohistochemistry • Alzheimer's Disease • In Vivo • Research • Animal Models • Neurodegeneration • Neuropathology • Neurodegenerative Diseases

Languages

English • French

Industries

Biotechnology

Resumes

Resumes

Thierry Bussiere Photo 1

Principal Investigator

View page
Location:
Cambridge, MA
Industry:
Biotechnology
Work:
Biogen Idec - Greater Boston Area since Feb 2008
Senior Scientist - Neurology Research
Biogen Idec - Greater Boston Area Feb 2006 - Jan 2008
Scientist II - Discovery Neurobiology
Biogen Idec - Greater Boston Area May 2005 - Jan 2006
Scientist I - Discovery Neurobiology
Elan Pharmaceuticals - San Francisco Bay Area Oct 2001 - Apr 2005
Post-doctoral Scientist
Mount Sinai School of Medicine - Greater New York City Area Apr 1999 - Oct 2001
Post-doctoral Fellow
Education:
Université des Sciences et Technologies de Lille (Lille I) 1995 - 1998
PhD, Sciences de la Vie et de la Sante - Neuroscience Faculte de Medecine Saint Antoine - Paris 1996 - 1997
DU, Genie Biologique et Medical Université Claude Bernard (Lyon I) 1993 - 1994
DEA, Neurosciences
Skills:
Neuroscience
Drug Discovery
Immunohistochemistry
Alzheimer's Disease
In Vivo
Research
Animal Models
Neurodegeneration
Neuropathology
Neurodegenerative Diseases
Languages:
English
French

Business Records

Name / Title
Company / Classification
Phones & Addresses
Thierry Bussiere
Scientist Neuropharmacology
BIOGEN IDEC INC
Biopharmaceutical Products · Pharmaceutical Preparations · Pharmaceutical Preparations Biological Products & Research · Other Biological Prod Mfg
14 Cambridge Ctr, Cambridge, MA 02142
425 W Capitol Ave STE 1700, Little Rock, AR 72201
1209 Orange St, Wilmington, DE 19801
10 Cambridge Ctr, Cambridge, MA 02142
(617) 621-3303, (617) 679-2000, (617) 679-3170, (617) 679-2617

Publications

Us Patents

Neuroactive Fragments Of App

View page
US Patent:
20080044406, Feb 21, 2008
Filed:
Jun 1, 2007
Appl. No.:
11/809552
Inventors:
Kelly Johnson-Wood - Scotts Valley CA, US
Peter Seubert - San Francisco CA, US
Thierry Bussiere - Cambridge MA, US
Assignee:
Elan Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61K 31/395
A61P 43/00
C07K 16/00
C12Q 1/00
C12Q 1/68
G01N 33/00
US Classification:
424130100, 435029000, 435006000, 530387100, 530387300, 800003000
Abstract:
The application provides novel neuroactive fragments of human amyloid precursor protein (APP). The fragments include sequence from the Aβ region of APP but also extend upstream. The fragments are soluble in aqueous solution most bands are about 10 kDa and above and do not correspond with the expected molecular weight of a dimer or trimer. The fragments and subfragments thereof can be used as immunogens in methods of immunotherapy to treat Alzheimer's and other amyloidogenic diseases characterized by deposits of Aβ in the brain. Antibodies to the part of the fragment upstream from APP or the interface between Aβ and the upstream sequence can also be used in such therapeutic method. The fragments are also useful as markers, which can be detected for diagnosis or prognosis of disease or for screening agents.

Anti-Beta-Amyloid Antibody For Treating Alzheimer's Disease

View page
US Patent:
20220372123, Nov 24, 2022
Filed:
Oct 21, 2020
Appl. No.:
17/770997
Inventors:
- Cambridge MA, US
- Schlieren, CH
Laura Nisenbaum - Cambridge MA, US
Raj Rajagovindan - Cambridge MA, US
Gersham Dent - Cambridge MA, US
John Beaver - Cambridge MA, US
Edward Plowey - Cambridge MA, US
Thierry Bussiere - Cambridge MA, US
Roger Nitsch - Zumikon, CH
International Classification:
C07K 16/18
A61P 25/28
Abstract:
Provided are methods for treating Alzheimer's disease in a human subject in need thereof comprising administration of multiple doses of an anti-beta-amyloid antibody (e.g., aducanumab) to the subject.

A Method Of Reducing Brain Amyloid Plaques Using Anti-Ab Antibodies

View page
US Patent:
20150315267, Nov 5, 2015
Filed:
Dec 6, 2013
Appl. No.:
14/650200
Inventors:
Thierry BUSSIERE - Belmont MA, US
Paul H. WEINREB - Andover MA, US
Thomas ENGBER - Acton MA, US
Kenneth RHODES - Belmont MA, US
Joseph ARNDT - Peabody MA, US
Fang QIAN - Southborough MA, US
Robert W. DUNSTAN - Bedford MA, US
Shailendra PATEL - Quincy MA, US
- Schlieren, CH
International Classification:
C07K 16/18
A61K 51/10
Abstract:
This disclosure relates to the use of anti-Aβ antibody or antigen-binding fragment thereof to reduce brain amyloid plaques, or minimizes the occurrence of microhemorrhage during chronic dosing of an anti-Aβ antibody or antigen-binding fragment thereof. For example, the disclosure relates to the method of reducing brain amyloid plaques, comprising administering to a subject an anti-Aβ antibody or antigen-binding fragment thereof that binds to the same epitope as BIIB037 antibody, wherein the administration can reduce amyloid plaques in brain without affecting vascular amyloid, and wherein BIIB037 antibody binds to an epitope comprising amino acids 3-6 of Aβ.
Control profile
Thierry H Bussiere from Belmont, MA, age ~56 Get Report